Investigating how ziltivekimab affects heart failure and inflammation
Official title: Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation
Run by Novo Nordisk A/S · NCT06200207 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new medication called ziltivekimab to see if it can help people with heart failure and inflammation feel better compared to a placebo.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 680 (estimated) |
| Sponsor | Novo Nordisk A/S Industry-sponsored |
| Drugs / interventions | ziltivekimab |
| Locations | 240 sites (Alexander City, Alabama and 239 other locations) |
| Trial ID | NCT06200207 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with heart failure (NYHA Class II-III) and elevated levels of inflammation markers.
✕Probably not a fit
Patients with heart failure who do not meet the specific inclusion criteria or have other significant health issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the efficacy of ziltivekimab, a new medication, in treating participants with heart failure and systemic inflammation. Participants will be randomly assigned to receive either ziltivekimab or a placebo, allowing researchers to compare the effects of the active drug against an inactive substance. The study is designed to last for up to 1 year and 4 months, focusing on specific cardiovascular biomarkers to determine eligibility. Ziltivekimab is not yet approved for use, making this trial crucial for understanding its potential benefits.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients suffering from heart failure and inflammation.
How similar studies have gone: While ziltivekimab is a novel approach, similar studies targeting inflammation in heart failure have shown promise, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Serum high-sensitivity C-reactive protein (hs-CRP) greater than or equal to 2 milligrams per liter (mg/L) at screening (visit 1) * Disease specific - cardiovascular: * N-terminal-pro-brain natriuretic peptide (NT-proBNP) greater than or equal to 225 picograms per milliliter (pg/mL) (375 pg/mL for participants with atrial fibrillation/flutter) at screening * Diagnosis of heart failure (New York heart association (NYHA) Class II-III) * Left ventricular ejection fraction (LVEF) greater than 40 percent documented by echocardiography within 12 months prior to or at screening (visit 1). The LVEF must be documented in medical records and the most recent measurement must be used to determine eligibility with no interim event signalling potential deterioration in ejection fraction (example myocardial infarction (MI) or heart failure (HF) hospitalisation) * Structural heart disease and/or functional heart disease documented by echocardiography within 12 months prior to or at screening (visit 1) showing at least one of the following: 1. Left atrial (LA) volume index greater than 34 milliliter per square meter (mL/m\^2) 2. LA diameter greater than or equal to 3.8 centimeter (cm) 3. LA length greater than or equal to 5.0 cm 4. LA area greater than or equal to 20 square centimeter (cm\^2) 5. LA volume greater than or equal to 55 milliliter (mL) 6. Intraventricular septal thickness greater than or equal to 1.1 cm 7. Posterior wall thickness greater than or equal to 1.1 cm 8. LV mass index greater than or equal to 115 gram per square meter (g/m\^2) in men or greater than or equal to 95 g/m\^2 in women h) E/e' (mean septal and lateral) greater than or equal to 10 i) e' (mean septal and lateral) less than 9 centimeter per second (cm/s) * No heart failure hospitalisations or urgent heart failure visits between screening and randomisation * Able to perform the 6-minute walk test (6MWT) at screening with a minimum distance of 100 metres * Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score lesser than 80 at screening Exclusion Criteria: * Medical conditions - cardiovascular: * Myocardial infarction, stroke, unstable angina pectoris, transient ischaemic attack, or heart failure hospitalisation within 30 days prior to screening (visit 1) * Systolic blood pressure greater than or equal to 180 millimeters of mercury (mmHg) at screening (visit 1). If the systolic blood pressure is 160-179 mmHg, the patient should be receiving greater than or equal to 3 antihypertensive drugs * Heart rate above 110 or below 40 beats per minute as evaluated on the Electrocardiogram (ECG) performed at screening (visit 1) * Planned coronary, carotid or peripheral artery revascularisation known during the screening period (visit 1) * Planned cardiac device or atrial flutter/atrial fibrillation ablation procedure known during the screening period (visit 1) * Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit 2) or any major surgical procedure planned at the time of randomisation (visit 2) * Heart failure due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, uncorrected more than moderate primary valve disease * Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including chronic obstructive pulmonary disease (COPD) * Any other condition judged by the investigator that could account for heart failure symptoms and signs (e.g., anaemia, hypothyroidism) * Medical conditions - infections/immunosuppression: * Clinical evidence of, or suspicion of, active infection at the discretion of the investigator
Where it's running
-
Valley Clinical Trials, Inc.
Northridge, California, United States Recruiting -
Clearwater Cardiovascular Consultants
Largo, Florida, United States Recruiting -
Kansas City VA Medical Center
Kansas City, Missouri, United States Recruiting -
PharmaTex Research
Amarillo, Texas, United States Recruiting -
Centro Médico CIMEL
Lanús Este, Buenos Aires, Argentina Recruiting -
CIPREC Pueyrredon
Buenos Aires, Argentina Recruiting
Show 44 more locations
-
Centro Cardiovascular Salta
Salta, Argentina Recruiting -
John Hunter Hospital
New Lambton Heights, New South Wales, Australia Recruiting -
The Prince Charles Hospital
Brisbane, Queensland, Australia Recruiting -
Diabetes Heart Research Centre
Toronto, Ontario, Canada Recruiting -
CPS Research
Waterloo, Ontario, Canada Recruiting -
St John's Medical College Hospital
Bengaluru, Karnataka, India Recruiting -
Sengupta Hospital and Research Institute
Nagpur, Maharashtra, India Recruiting -
All India Institute of Medical Sciences (AIIMS), Bhubaneswar
Bhubaneswar, Odisha, India Recruiting -
Hospital Sultanah Aminah
Johor Bahru, Johor, Malaysia Recruiting -
University Malaya Medical Centre
Kuala Lumpur, Kuala Lumpur, Malaysia Recruiting -
Hospital Raja Perempuan Zainab II
Kota Bharu, Kelantan, Malaysia Recruiting -
Trialmed Sp. z o. o.
Piotrkow Trybunalski, Poland Recruiting -
Erciyes Üniversitesi Hastanesi- Kardiyoloji
Kayseri, Turkey (Türkiye) Recruiting -
Advanced Cardiovascular, LLC
Alexander City, Alabama, United States Completed -
Eastern Shore Rsrch Inst, LLC
Fairhope, Alabama, United States Active not recruiting -
Cardiology & Medicine Clinic
Little Rock, Arkansas, United States Completed -
Valley Clinical Trials, Inc.
Northridge, California, United States Active not recruiting -
UCI Health
Orange, California, United States Completed -
South California Heart Spc
Pasadena, California, United States Active not recruiting -
Clearwater Cardiovascular Consultants
Largo, Florida, United States Completed -
Ocala Cardiovascular Research
Ocala, Florida, United States Active not recruiting -
Ormond Beach Clinical Research
Ormond Beach, Florida, United States Active not recruiting -
St Johns Ctr Clin Rsch-St. Aug
Saint Augustine, Florida, United States Active not recruiting -
GA Arrhythmia Cons & Rsch Inst
Macon, Georgia, United States Active not recruiting -
Velocity Clin Rsrch - Savannah
Savannah, Georgia, United States Completed -
Chicago Medical Research LLC
Hazel Crest, Illinois, United States Completed -
UofL Health Care Outpatient
Louisville, Kentucky, United States Active not recruiting -
Maryland Cardiovascular Specialists - Baltimore
Baltimore, Maryland, United States Completed -
MD Medical Research
Oxon Hill, Maryland, United States Completed -
Cardio and Vascular Assoc-CAVA
Bloomfield Hills, Michigan, United States Active not recruiting -
Millennium Cardiology
Farmington Hills, Michigan, United States Active not recruiting -
Kansas City VA Medical Center
Kansas City, Missouri, United States Completed -
Washington University
St Louis, Missouri, United States Active not recruiting -
Renown Regional Medical Center
Reno, Nevada, United States Active not recruiting -
Long Island Cardiovascular Consultants PC
Lake Success, New York, United States Completed -
Mount Sinai Hosp at NYC
New York, New York, United States Active not recruiting -
Northwell Health Phys Cardio
Riverhead, New York, United States Active not recruiting -
University Of North Carolina At Chapel Hill
Chapel Hill, North Carolina, United States Active not recruiting -
AMS Cardiology
Horsham, Pennsylvania, United States Active not recruiting -
Univ of Pennsylvania Hospital
Philadelphia, Pennsylvania, United States Active not recruiting -
PharmaTex Research
Amarillo, Texas, United States Active not recruiting -
University of Texas Southwestern Medical Center
Dallas, Texas, United States Active not recruiting -
David Turbay, MD, PLLC
El Paso, Texas, United States Active not recruiting -
Private Practice Leadership LLC.
Katy, Texas, United States Completed
+190 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: Novo Nordisk
- Email: clinicaltrials@novonordisk.com
- Phone: (+1) 866-867-7178
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
-
NT-proBNP–guided heart failure screening for people 65+ in rural China
This study tests whether using NT-proBNP blood tests to guide heart failure screening in adults 65 and older in rural China can find unrecognized heart problems more effectively than symptom-based screening.
-
Voice-based detection of heart failure deterioration using Noah Labs Vox
This study tests whether a voice-analysis app can flag worsening heart failure in adults by comparing its alerts to standard weight-based monitoring.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.